Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE-MS-2: Diroximel Fumarate vs Dimethyl Fumarate GI Tolerability in RRMS
NCT03093324Phase 3Completed
- Sponsor
- Biogen
- Start
- Mar 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of diroximel fumarate in multiple sclerosis (MS) (2 arms), sponsored by Biogen. Primary endpoint: Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days at 5 weeks. Started Mar 2017; status: completed.
02
Drugs
diroximel fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03093324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093324.